Role of incretins in energy metabolism and weight changes after smoking cessation
Authors:
MUDr. Alexandra Pánková
Authors‘ workplace:
Ústav hygieny a epidemiologie 1. LF UK a VFN v Praze
; Centrum pro závislé na tabáku 3. interní kliniky 1. LF UK a VFN v Praze
Published in:
Čas. Lék. čes. 2016; 155: 151-153
Category:
Review Article
Overview
Incretine-based therapies are frequently used to treat patients with type 2 diabetes. Some of these drugs are used to induce weight loss. Liraglutide, a glucagon-like peptide 1 receptor agonist, was recently approved for the treatment of obesity. Smoking cessation is associated with weight gain. The mechanism responsible for the increase in body weight post cessation remains unclear. While increased caloric intake may play a role, weight gain may also be linked to nicotine, which has been shown to stimulate smokers’ basal metabolic rate. The effect of incretines on body weight and energy metabolism after smoking cessation is unclear. Recently published data suggests that incretine hormones may not be involved in the above mentioned changes.
Keywords:
smoking cessation , body weight, glucagon-like peptide 1, glucose-dependent insulinotropic peptide, leptin
Sources
1. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124: S3–S18.
2. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig 2010; 1: 8–23.
3. Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 2014; 16: 9–21.
4. Deane AM, Nguyen NQ, Stevens JE et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95: 215–221.
5. Meier JJ, Gethmann A, Gotze O et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49: 452–458.
6. Williams DL,Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide 1 plays a physiological role in satiety. Endocrinology 2009; 150: 1680–1687.
7. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010; 123: S28–S37.
8. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–2157.
9. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011; 33: 511–527.
10. Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci 2011; 1243: E55–E74.
11. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819–837
12. Flint A, Raben A, Rehfeld JF et al. The effect of glucagon-like peptide 1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 2000; 24: 288–298.
13. Dirksen C, Jorgensen NB, Bojsen-Moller KN et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 2012; 55: 1890–1901.
14. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 1987; 2: 1300–1304.
15. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409–1439.
16. Azimova K, Juan ZS, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J 2014; 14: 616–632.
17. Meier JJ, Nauck MA. Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 2008; 4: 606–607.
18. Vollmer K, Holst JJ, Baller B et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678–687.
19. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301–307.
20. Haluzík M, Urbanová M, Trachta P. Léčba diabetes mellitus 2. typu GLP-1 agonisty. Vnitř Lék 2011; 57(4): 411–415.
21. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153–165.
22. Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med 2014; 25: 407–414.
23. Bose M, Oliván B, Teixeira J et al. Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg 2009; 19: 217–229.
24. Haluzík M, Mráz M, Svačina Š. Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects. Drug Saf 2014; 37: 1003–1010.
25. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929–2940.
26. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004; 36: 761–765.
27. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012; 109: 1681–1685.
28. Drucker DJ. Incretin-based therapy and the quest for sustained improvements in B-cell health. Diabetes Care 2011; 34: 2133–2135.
29. le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780–785.
30. Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009; 150: 94–103.
31. Falken Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227–2235.
32. Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opin Pharmacother 2014; 15: 2487–2500.
33. Albanes D, Jones DY, Micozzi MS, Mattson ME. Associations between smoking and body weight in the U.S. population: analysis of NHANES II. Am J Public Health 1987; 77: 439–44.
34. Molarius A, Seidell JC, Kuulasmaa K et al. Smoking and relative body weight: an international perspective from the WHO MONICA Project. J Epidemiol Community Health 1997; 51: 252–260.
35. Klesges RC, Meyers AW, Klesges LM, La Vasque ME. Smoking, body weight and their effects on smoking behavior: A comprehensive review of the literature. Psychol Bull 1989; 106: 204–230.
36. Klesges RC, Winders SE, Meyers AW et al. How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consul Clin Psychol 1997; 65: 286–291.
37. Aubin HJ, Farley A, Lycett D et al. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ 2012; 10: 345: e4439.
38. Chiolero A, Jacot-Sadowski I, Faeh D et al. Association of cigarettes smoked daily with obesity in a general adult population. Obesity 2007; 15: 1311–1318.
39. Hughes JR, Gust SW, Skoog K et al. Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiat 1991; 48: 52–59.
40. Henningfield JE, London ED, Pogun S. Nicotine psychopharmacology. Preface. Pharmacology. In: Henningfield JE, London ED, Pogun S. Handbook of experimental pharmacology 192. Springer, 2009; v–viii.
41. Yoshida T, Yoshioka K, Hiraoka N, Kondo M. Effect of nicotine on norepinephrine turnover and thermogenesis in brown adipose tissue and metabolic rate in MSG obese mice. J Nutr Sci Vitaminol 1990; 36: 123–130.
42. Hofstetter A, Schutz Y, Jequier E, Wahren J. Increased 24-hour energy expenditure in cigarette smokers. NEJM 1986; 314: 79–82.
43. Dallosso HM, James WP. The role of smoking in the regulation of energy balance. Int J Obes 1984; 8: 365–375.
44. Chatkin R, Chatkin JM. Smoking and changes in body weight: Can physiopathology and genetics explain this association? J Bras Pneumol 2012; 33: 712–719.
45. Mineur YS, Abizaid A, Rao Y et al. Nicotine decreases food intake through activation of POMC neurons. Science 2011; 332: 1330–1332.
46. Gritz ER, Ippoliti A, Jarvik ME et al. The effect of nicotine on the delay of gastric emptying. Aliment Pharm Therap 1988; 2: 173–178.
47. Miller G, Palmer KR, Smith B et al. Smoking delays gastric emptying of solids. Gut 1989; 30: 50–53.
48. Kadota K, Takeshima F, Inoue K et al. Effects of smoking cessation on gastric emptying in smokers. J Clin Gastroenterol 2010; 44: e71–e75.
49. Aveyard P, Lycett D, Farley A. Managing smoking cessation‐related weight gain. Pol Arch Med Wewn 2012; 122: 494–498.
50. Stadler M, Tomann L, Storka A et al. Effects of smoking cessation on β-cell function, insulin sensitivity, body weight, and appetite. Eur J Endocrinol 2014; 170: 219–217.
51. Pánková A, Králíková E, Kaválková P et al. Serum leptin and incretins levels after smoking cessation and their possible role in the smoking-related changes of energy homeostasis. Physiol Res. 2016 Mar 15. Epub ahead of print.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Surgical treatment of lower extremity peripheral nerve injuries
- Vesicoureteric reflux in children: many questions still unanswered
- Faecal incontinence – serious medical and social issue
- Hyponatremia in children: from pathophysiology to therapy